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On the surface these studies appear to 
conflict with the work of Somervaille and 
Cleary, in that the immunophenotype of 
AML-SCs is quite different. However, it is 
actually not possible to directly compare 
the reports due to substantial differences 
in methodology. The two groups employed 
different populations of normal cells for the 
original transduction with MLL-AF9, differ-
ent strategies for functional characteriza-
tion of AML-SCs, and different methods to 
estimate the frequency of AML-SCs. Taken 
together, these factors could certainly lead 
to varying interpretations and conclusions, 
despite the common feature of studying 
MLL-AF9-induced leukemias.
Considered more broadly, the reports of 
Somervaille and Cleary (2006) and Krivtsov 
et al. (2006) serve to emphasize an intrigu-
ing point—the basic properties of AML-SCs 
may be relatively heterogeneous and may 
vary as a function of genetics and develop-
mental origin. Figure 1 illustrates some of 
the hypothetical steps leading to the gen-
eration of AML-SCs. When one considers 
the specific type of initial mutation (step 1), 
the originating target cell (step 2), subse-
quent differentiation or lack thereof (step 3), 
and the types of subsequent mutations that 
may occur (step 4), the number of possible 
permutations in the genesis of AML-SCs is 
quite large. Furthermore, given the inher-
ently unstable genome of most malignant 
cells and possible changes evoked by 
challenge with various drug therapies, the 
resulting phenotype of human AML-SCs is 
potentially even more complex.
Given the issues above, several ques-
tions regarding the evolution and properties 
of AML-SCs should be considered. Perhaps 
most importantly, while the elegant studies 
in mouse models have indicated differing 
paths by which leukemia stem cells may 
arise, are any of these scenarios prevalent 
in primary human disease? To date, the only 
direct studies indicating a GMP-like origin 
for an acute form of myeloid disease is the 
report by Jamieson et. al. that describes 
studies of blast crisis CML (chronic myeloid 
leukemia) (Jamieson et al., 2004). CML is 
unique among myeloid leukemias in that it 
displays an overt and well-defined pathology 
at each stage of progression, and thereby 
permits the isolation and analysis of stem 
cells from early (chronic) and late (blast 
crisis) forms of disease. However, aside 
from CML, in five of the other eight major 
subtypes of AML (designated as FAB types 
M0, M1, M2, M4, and M5), the only AML-
SCs characterized to date are both rare and 
phenotypically similar to HSCs (Bonnet and 
Dick, 1997). Therefore, while the data from 
mouse models are compelling, their direct 
relevance to human disease remains a 
largely unanswered question. Indeed, from 
a genetic perspective, evidence suggests 
that transformation of human cells is more 
complex than murine cells (Rangarajan and 
Weinberg, 2003); thus, findings from one 
species should be validated in the other. 
Going forward, it will be important to iden-
tify and isolate human counterparts to the 
entities described thus far from murine stud-
ies. Such efforts may come from the analy-
sis of primary specimens, as described by 
Jamieson et al., or may also derive from the 
generation of better experimental models. In 
this regard, the studies cited above using 
gene transfer into normal murine progeni-
tor cells have likely established an important 
precedent for future efforts using primary 
human cells.
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AKT, a key regulator of cell proliferation and survival, is commonly dysregulated in human cancers. Activated AKT kinase is 
oncogenic and required for tumorigenesis in PTEN-deficient animals. However, the importance of AKT in mediating transforma-
tion by other oncogenes and which of its targets are necessary for this process are poorly understood. In this issue of Cancer 
Cell, Skeen et al. show that AKT is required for transformation by mutant H-Ras and for experimental skin carcinogenesis. 
Moreover, the effects of AKT are mediated predominantly or solely via mTORC1. This suggests that AKT or mTOR inhibitors 
will be useful treatments for many cancers.The PI3K/AKT kinase pathway is a cen-
tral regulator of cell metabolism, prolif-
eration, and survival and is dysregulated 
by oncogenic events in a substantial 254	fraction of tumors. Constitutive activa-
tion of growth factor receptors, mutation 
of PI3K, and inactivation of the PTEN 
phosphatase cause the activation of PI3K signaling in the majority of glioblastomas 
and breast, endometrial, and prostate 
cancers, among others. Furthermore, 
PI3K is an effector of RAS function and cancer cell october	2006
	 p r e v i e w shas been shown to be required for both 
the development and maintenance of 
tumors driven by mutant H-Ras (Lim and 
Counter, 2005).
PI3K has a multitude of downstream 
targets, including AKT, mutations of 
which are oncogenic and occasionally 
present in human tumors. AKT activation 
stimulates proliferation and desensitizes 
cells to apoptotic stimuli. Recently, Hay 
and colleagues showed that AKT1 is 
required for the development of tumors 
in Pten+/− mice (Chen et al., 2006). This 
result proved that AKT is a target of PI3K 
that is necessary for transformation driv-
en by PTEN haploinsufficiency. It left 
open the question of whether AKT was 
important in mediating transformation by 
other oncogenes, and through which tar-
gets AKT exerted those effects.
These issues are addressed in a fol-
low-up paper in this issue of Cancer Cell. 
Skeen et al. (2006) show that the prolif-
eration of mouse embryonic fibroblasts 
from Akt1 null mice is impaired, as is their 
sensitivity to transformation by H-Ras in 
combination with dominant-negative p53. 
They further demonstrate that tumorigen-
esis in mutant H-Ras transgenic mice 
and in a carcinogen-induced murine skin 
cancer model are markedly reduced in 
the Akt1 null background. Although PI3K 
is recognized as an important effector of 
activated Ras, these data strongly sug-
gest that, at least in these contexts, PI3K 
activation of AKT is necessary for trans-
formation and, perhaps, a reasonable 
target for therapy.
Next, Skeen et al. investigate wheth-
er mTORC1 is the downstream target of 
AKT that mediates its effects on trans-
formation. AKT signals through a vari-
ety of downstream targets that affect 
transcription, metabolism, and apopto-
sis. Phosphorylation of TSC2 by AKT 
relieves the inhibition of Rheb/mTORC1 
by the TSC1/2 complex and serves to 
activate translation via the effects of 
mTOR on p70S6 kinase and 4EBP1 
(Ruggero and Sonenberg, 2005). Tsc2 
is a tumor suppressor gene, germline 
mutations of which are associated with 
tuberous sclerosis. Inactivation of TSC2 
causes tumors by constitutively activat-
ing mTOR. mTOR activation also inhib-
its AKT via an S6K-dependent feedback 
mechanism (Harrington et al., 2004; Um 
et al., 2004).
In Tsc2 null cells, therefore, mTORC1 
is activated and AKT is inhibited. Skeen 
et al. show that these cells have normal 
rates of proliferation and are quite sensi-
cancer cell october	2006	tive to transformation by H-Ras. In these 
cells, reducing Raptor expression with 
shRNA decreases mTOR activity and, by 
relieving feedback, increases AKT activ-
ity, yet sensitivity to H-Ras is reduced. 
Conversely, introducing activated Rheb 
into Akt1/2 double null cells restores 
their transformability. This work convinc-
ingly shows that, in this system, the AKT 
dependence of H-Ras transformation is 
mediated by mTORC1.
These findings have important impli-
cations. They suggest that other down-
stream targets of AKT are dispensable 
for its role in transformation by H-Ras. 
Furthermore, the work implies that drugs 
that cause even partial inhibition of AKT 
activity could be extremely useful for the 
treatment of many classes of tumors, 
including those with Ras, PI3K, and Pten 
mutations. Finally, Skeen et al. show that 
mTORC1 inhibition with rapamycin inhib-
its transformation by H-RAS. By relieving 
feedback inhibition, rapamycin causes 
increased AKT activity in some tumors 
(O’Reilly et al., 2006). This has raised the 
concern that relief of feedback inhibition 
could attenuate the effects of rapamycin 
or even cause tumors to worsen after 
treatment with the drug. However, if the 
only important downstream target of AKT 
is mTOR, this should not be a problem. 
The data in Skeen et al. support the idea 
that mTOR inhibitors should be useful in 
a broad range of tumors.
Skeen et al. studied the transforma-
tion of murine cells, mostly fibroblasts, 
with mutant H-Ras. It is worth pointing 
out some areas in which their conclu-
sions diverge from those drawn from 
observations in other systems. Tsc2 
mutations have not been detected in 
sporadic tumors. Tumors that arise in a 
Tsc2 mutant background, in humans and 
in model systems, are indolent and have 
reduced AKT signaling. However, PTEN 
haploinsufficiency restores AKT signal-
ing and causes more rapidly growing, 
virulent tumors (Manning et al., 2005). 
These findings suggest that activation of 
mTOR alone is not sufficient to mediate 
AKT-dependent transformation in this 
system and that AKT must have other 
downstream targets.
It is possible that mTORC1 is the 
dominant AKT target in cells trans-
formed with mutant Ras, but not in oth-
ers. Several RAS effectors are necessary 
for its induction of transformation. RAS/
RAF/MAPK signaling plays important 
roles in regulating transcription and 
apoptosis and may complement mTOR and render other AKT targets superflu-
ous (Rajasekhar et al., 2003; She et al., 
2005). However, whereas mutant H-Ras 
is quite transforming in murine systems 
and used ubiquitously in laboratory stud-
ies, it is rare in human tumors, in which 
K-Ras and N-Ras mutations dominate. It 
is very possible that mutant H-Ras has 
different properties than the others and 
may be less relevant to human systems.
Finally, this work and that of others 
strongly suggests the utility of both AKT 
and mTOR inhibitors in the treatment of 
human cancer. Previous studies sug-
gest that tumors with mutational acti-
vation of PI3K or AKT or loss of PTEN 
function would be especially sensitive 
to mTOR inhibition (Neshat et al., 2001; 
Podsypanina et al., 2001). This work 
adds tumors with Ras mutation to the 
list. A large percentage of human tumors 
should therefore be sensitive to rapamy-
cin-like drugs. Unfortunately, this has not 
proven to be the case. Three analogs 
of rapamycin that effectively inhibit the 
Raptor-mTOR complex have been tested 
extensively in patients with advanced can-
cer. These drugs have modest anticancer 
activity in a minority of patients, including 
some with renal cancer, sarcomas, and 
mantle cell lymphoma. However, results 
have been quite disappointing, especially 
in tumors characterized by a high fre-
quency of Pten mutation (glioblastoma, 
prostate cancer) or K-Ras mutation (pan-
creatic and lung cancer). There are many 
possible reasons for resistance, including 
ineffective target inhibition and coexist-
ing mutations that activate other signal-
ing pathways. It has been suggested that 
the rapamycin-induced activation of AKT 
might attenuate its effects. In this case, 
combined therapy with mTOR and PI3K/
AKT inhibitors should be useful. In sup-
port of this idea, Weiss et al. have shown 
that a drug that inhibits both mTOR and 
PI3K has enhanced activity in glioblas-
toma models (Fan et al., 2006).
One of the major goals of cancer biol-
ogy is the development of rational clinical 
strategies based on an understanding 
of the biology of transformation. Clinical 
trials of specific inhibitors of key signal-
ing proteins provide valuable information 
about the role played by the target in the 
tumor. The effects of imatinib in patients 
with chronic myelogenous leukemia are 
consistent with the central importance of 
BCR-ABL in this disease. The role played 
by mTOR in malignancy is clearly more 
complex. Just as data from model systems 
inform the development of clinical strate-255
	 p r e v i e w sgies, analysis of laboratory data should 
take into account the results of clinical tri-
als. The results of the clinical trials of rapa-
mycin in cancer should be incorporated 
into our thinking about the role of mTOR 
signaling in transformation.
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